Drug intelligence / Profile preview

TCT-001

Development stage: Unknown
Lead developer: Tcelltech
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

TCT-001 is an investigational T-cell receptor (TCR) engineered T-cell therapy developed by Tcelltech for the treatment of glioblastoma. This cell therapy involves the genetic modification of T cells to express a specific TCR capable of recognizing glioblastoma-associated antigens presented on the surface of tumor cells. Once administered, these engineered T cells are designed to specifically target and eliminate malignant cells within the brain. Tcelltech has completed preclinical development for TCT-001 and anticipates initiating Phase 1 clinical trials in 2026.

Other names: Tcelltech glioblastoma TCR therapy

Beyond the preview

Go deeper on TCT-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TCT-001.

Explore the full profile